Skip to Content

A New Vaccine Against Multiple Sclerosis

Initial human tests show the vaccine appears safe and triggers beneficial changes in the brain.
August 14, 2007

An experimental DNA vaccine against multiple sclerosis (MS) appears safe in early human tests and shows signs of effectiveness, according to a paper published Monday in the online version of the Archives of Neurology.

In MS, the immune system attacks the fatty coating, known as myelin, protecting nerve cells in the brain and spinal cord, eventually destroying nerve cells’ ability to communicate. The cause of the disease is unknown.

In the study, headed by Amit Bar-Or of the Montreal Neurological Institute in Canada, patients were given a vaccine made up of one of the protein components of myelin. The idea is that the vaccine will damp the body’s tendency to attack myelin.

While larger studies are needed to determine if the vaccine will truly help MS patients, initial results were promising. The vaccine appears safe and showed early signs of a beneficial effect on the immune system: the number of immune cells in the spinal fluid that attack myelin was reduced in a small subset of patients who underwent lumbar puncture. A larger study of the vaccine is now under way.

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.